PEVM — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2025-11-12

• Gain on change in fair value of derivative liability - 13 - 602

• * The shares are presented on a retrospective base to reflect the Company’s reverse stock split effected on July 31, 2025.

• For the three months ended September 30, 2025 and 2024, our revenues were $2.5 million and $4.8 million, respectively. Our total revenue decreased by $2.3 million, or 47.9%, primarily because we completed the acquisition of Proterra transit business unit in January 2024. With the acquisition, we wer…

• For the three and nine months ended September 30, 2025 and 2024, our revenue breakdown by major categories for relevant periods was as follows:

• Our other expenses for the three months ended September 30, 2024, was $1.0 million, primarily due to loss on change in fair value of warrant liability of $0.2 million and interest expense of $0.8 million, from short-term loan and debt discount amortization of convertible note.

Text removed vs the prior filing · source: 10-Q · 2025-08-14

• Loss on warrants issued during private placement - - - (7,432)

• Gain on change in fair value of derivative liability - 647 - 589

• *The shares are presented on a retrospective base to reflect the Company’s reverse stock split effected on July 31, 2025.

• For the six months ended June 30, 2025 and 2024, our revenues were $7.2 million and $21.5 million, respectively. Our total revenue decreased by $14.2 million, or 66.7%, primarily because we completed the acquisition of Proterra transit business unit in January 2024. With the acquisition, we were abl…

• For the three and six months ended June 30, 2025 and 2024, our revenue breakdown by major categories for relevant periods was as follows:

Text added vs the prior filing · source: 10-Q · 2025-11-12

• On November 3, 2025, we received a letter from the Council indicating that it has deemed the appeal abandoned due to our failure to submit to the Council any arguments in support of our appeal and that the Staff will proceed to delist the Company’s securities in accordance with the June 9, 2025 Pane…

• We have taken steps to address the identified deficiencies. On April 18, 2025, we held our 2024 annual meeting of stockholders and believe we have regained compliance with Listing Rule 5620(a). On May 30, 2025, we filed our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and …

• We are continuing to take actions to regain full compliance with Nasdaq’s listing requirements. In particular, our board of directors implemented a 1-for-5 reverse stock split of its common stock effective as of July 31, 2025, which was intended to restore compliance with Rule 5550(a)(2).

• There can be no assurance that these actions will result in the relisting on Nasdaq. We remain committed to pursuing all reasonable and strategic options to regain compliance and restore our listing on a national securities exchange.

Text removed vs the prior filing · source: 10-Q · 2025-08-14

• Notwithstanding the Panel’s decision, we have taken steps to address the identified deficiencies. On April 18, 2025, we held our 2024 annual meeting of stockholders and believe we have regained compliance with Listing Rule 5620(a). On May 30, 2025, we filed our Annual Report on Form 10-K for the fis…

• We are continuing to take actions to regain full compliance with Nasdaq’s listing requirements. In particular, our board of directors has implemented a 1-for-5 reverse stock split of its common stock effective as of July 31, 2025, which is intended to restore compliance with Rule 5550(a)(2).

• While there can be no assurance that these actions will result in relisting on Nasdaq or that the review by the Council will be successful, we remain committed to pursuing all reasonable and strategic options to regain compliance and restore our listing on a national securities exchange.